Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, randomized, multicenter phase II clinical study to evaluate the efficacy of Proxalutamide tablets in the treatment of metastatic castration-resistant prostate cancer

Next Previous
Trial Profile

An open, randomized, multicenter phase II clinical study to evaluate the efficacy of Proxalutamide tablets in the treatment of metastatic castration-resistant prostate cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pruxelutamide (Primary)
  • Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
  • Focus Therapeutic Use

Most Recent Events

  • 06 Jul 2023 Results assessing safety and efficacy of proxalutamide for men with metastatic castration-resistant prostate cancer, published in the International Journal of Cancer.
  • 18 Mar 2021 New trial record
  • 13 Feb 2021 Results (n=108) data cut off: June 30, 2019 presented at the 2021 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top